Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07219927 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:

Name: Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: — clinical trial record (NCT07219927)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhaseNot specified

SponsorSupernus Pharmaceuticals, Inc.

Started2025-03-31

View on ClinicalTrials.gov ↗

Supernus Pharmaceuticals, Inc.

10 trials monitored

See 1 trial at risk

Parkinson's Disease

1,423 trials monitored

See 59 trials at risk

Real-World Participants Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease

Trial Details

NCT Number	NCT07219927
Lead Sponsor	Supernus Pharmaceuticals, Inc.
Conditions	Parkinson Disease
Enrollment	120 participants
Start Date	2025-03-31
Primary Completion	2027-08-01 (estimated)
Study Completion	2027-08-01 (estimated)
Updated on ClinicalTrials.gov	2025-10-22